- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
Patent holdings for IPC class A61P 37/06
Total number of patents in this class: 6207
10-year publication summary
|
188
|
198
|
197
|
311
|
528
|
493
|
676
|
715
|
674
|
183
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11238 |
107 |
| The Regents of the University of California | 18943 |
55 |
| Chugai Seiyaku Kabushiki Kaisha | 1259 |
49 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3314 |
46 |
| Ono Pharmaceutical Co., Ltd. | 454 |
46 |
| F. Hoffmann-La Roche AG | 7958 |
42 |
| Takeda Pharmaceutical Company Limited | 2961 |
40 |
| Selecta Biosciences, Inc. | 190 |
39 |
| Genentech, Inc. | 3742 |
37 |
| Daiichi Sankyo Company, Limited | 1829 |
37 |
| Astellas Pharma Inc. | 1145 |
36 |
| Bristol-myers Squibb Company | 5080 |
34 |
| Janssen Biotech, Inc. | 1347 |
32 |
| Amgen Inc. | 3779 |
27 |
| Osaka University | 3143 |
27 |
| The University of Tokyo | 3903 |
27 |
| Incyte Corporation | 918 |
24 |
| Hoffmann-La Roche Inc. | 3060 |
23 |
| Eli Lilly and Company | 3645 |
23 |
| Regeneron Pharmaceuticals, Inc. | 3650 |
23 |
| Other owners | 5433 |